lutetium lu 177 vipivotide tetraxetan,177lu-psma-617,cabazitaxel
emcure,sanofi,novartis
[' vision', 'therap ']
do we need fdg pet! note that 51/291 pts (17%) excluded from therap based on fdg/psma discordant disease, supports use of both imaging modalities. this is soc in to choose pts. vision did not require fdg pet so seems less likely in to be used #asco2022
An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family